# Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma

> **NCT01644799** · PHASE1 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 8 (actual)

## Conditions studied

- Recurrent Follicular Lymphoma

## Interventions

- **DRUG:** idelalisib
- **DRUG:** lenalidomide

## Key facts

- **NCT ID:** NCT01644799
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2014-08
- **Final completion:** 2017-05
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2018-01-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01644799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01644799, "Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01644799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*